secwatch.observer — SEC 8-K summary
======================================

Issuer:     eFFECTOR Therapeutics, Inc. (—)
CIK:        0001828522
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-135263
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

eFFECTOR Q1 net loss $8.8M; tomivosertib NSCLC fails; zotatifin advance
-----------------------------------------------------------------------

- Net loss of $8.8M ($2.16 per share) vs $10.0M ($5.96 per share) in Q1 2023.
- Cash, equivalents, and short-term investments $25.4M at March 31, 2024; raised $15M in Jan 2024 registered direct offering.
- Zotatifin ZFA triplet dose escalation at 0.14 mg/kg; RP2D expected H2 2024.
- Tomivosertib KICKSTART trial in NSCLC: HR 0.62 (p=0.21), missed pre-specified 0.2 threshold; no path forward.
- R&D expense decreased to $5.3M from $6.6M; cash runway into Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828522/000119312524135263/0001193125-24-135263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828522/000119312524135263/d822499d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-135263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer